A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Results
  • Discussion
  • Disclosures
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

This protocol details the isolation of live immune and non-immune populations from the mouse lung at a steady state and following influenza infection. It also provides gating strategies for identifying epithelial and myeloid cell subsets.

Abstract

The lung is continuously exposed to pathogens and other noxious environmental stimuli, rendering it vulnerable to damage, dysfunction, and the development of disease. Studies utilizing mouse models of respiratory infection, allergy, fibrosis, and cancer have been critical to reveal mechanisms of disease progression and identify therapeutic targets. However, most studies focused on the mouse lung prioritize the isolation of either immune cells or epithelial cells, rather than both populations concurrently. Here, we describe a method for preparing a comprehensive single-cell suspension of both immune and non-immune populations suitable for flow cytometry and fluorescence-activated cell sorting. These populations include epithelial cells, endothelial cells, fibroblasts, and a variety of myeloid cell subsets. This protocol entails bronchoalveolar lavage and subsequent inflation of the lungs with dispase. Lungs are then digested in a liberase mixture. This method of processing liberates a variety of diverse cell types and results in a single-cell suspension that does not require manual dissociation against a filter, promoting cell survival and yielding high numbers of live cells for downstream analyses. In this protocol, we also define gating schemes for epithelial and myeloid cell subsets in both naïve and influenza-infected lungs. Simultaneous isolation of live immune and non-immune cells is key for interrogating intercellular crosstalk and gaining a deeper understanding of lung biology in health and disease.

Introduction

The lung is composed of the airways, alveoli, and interstitium. Immune and non-immune cells reside within these compartments to contribute to both homeostatic lung function (gas exchange) and host defense against environmental insults, such as viral infection. The large and small airways, or the bronchi and bronchioles, are lined by epithelial cells. The predominant epithelial cells in these regions are club and ciliated cells which are responsible for secreting protective molecules and facilitating mucociliary clearance1. The alveoli are the most distal structures in the lung, lined by two epithelial cell types, alveolar type I cells (ATIs) and alveolar type II cells (ATIIs). ATIs are responsible for gas exchange, and ATIIs secrete and recycle surfactants to ensure appropriate surface tension2,3. ATIIs are self-renewing and can also differentiate into ATIs, a role especially relevant following lung damage4. Additionally, ATIIs provide a supportive niche for the major immune cell type populating the alveolar niche, alveolar macrophages (AMs)5,6. Beyond the epithelium, fibroblasts, endothelial cells, and interstitial macrophages (IMs) (which can be both nerve- and vessel-associated) comprise the interstitium7,8,9,10. In response to infection and injury, numerous lung cells die, and immune cells, including monocytes and neutrophils, infiltrate into the tissue11,12. Lung-infiltrating monocytes differentiate into macrophages and can contribute to the macrophage compartment long-term13.

Current methods to prepare single-cell suspensions from the mouse lung are generally collagenase-based and require physical dissociation of tissue14. This can result in low numbers of viable non-immune cell populations. Some protocols to isolate epithelial cells are dispase-based and yield higher proportions of live epithelial cells; however, these protocols generally do not investigate immune cell yields and viability15,16,17. Flow cytometry is a common method used to distinguish cell populations within a digested tissue. At baseline, flow cytometry gating for AMs, IMs, monocytes, and neutrophils is clearly delineated. However, during inflammation, the gating process becomes variable and challenging to interpret due to the continuum in surface marker expression of infiltrating monocytes differentiating into macrophages. Therefore, the protocol presented herein also outlines gating strategies to identify myeloid cell populations of interest following infection.

Robust dissociation of lung epithelial and myeloid cells is essential to discern their homeostatic and inflammatory functions. A method to isolate these cell compartments in parallel will enable the downstream analyses of key cell types that both maintain health and drive disease. A schematic overview of this protocol's workflow can be found in Figure 1.

Protocol

This protocol complies with the guidelines of the Institutional Animal Care and Use Committee at Harvard Medical School (Grant numbers: R35GM150816 and P30DK043351). Female C57BL/6J mice aged 8-12 weeks were used for the experiments. This protocol is also suitable for male mice. The details of the reagents and equipment used in this study are provided in the Table of Materials.

1. Preparation of materials

  1. Thaw necessary enzymes on ice, including dispase, liberase, and DNAse.
  2. Prepare other necessary reagents. Fill a 10 mL syringe with 5 mL of 2 mM EDTA in DPBS and fit it with a 27 G needle. Fill the 1 mL syringe with DPBS and attach the catheter.

2. Harvesting the lungs

  1. Euthanize the mouse by intraperitoneal injection of 400-500 mg/kg and 25-100 mg/kg ketamine/xylazine mixture (following institutionally approved protocols). Proceed with dissection once the mouse is unresponsive to the foot pad pinch (~5 min).
    NOTE: A ketamine/xylazine mixture is used for euthanasia instead of carbon dioxide to prevent suffocation-induced hemorrhage and immune cell infiltration that can confound results.
  2. Spray the mouse with 70% ethanol. Dissect the mouse using fine surgical scissors and #7 forceps. Make an incision into the abdomen using scissors and cut laterally through the peritoneum.
    1. Make a small cut into the diaphragm to release the vacuum. Cut the diaphragm and lower rib cage out of the body cavity to expose the lungs and heart.
  3. Perfuse the lungs with 5 mL of 2 mM EDTA in DPBS in a 10mL syringe fitted with a 27 G needle. Perfusion is performed by entering the base of the heart with the needle, directed from the right into the left ventricle, and slowly dispensing liquid from the syringe18.
    NOTE: Perfusion should be performed slowly to prevent ruptured vasculature.
  4. Open the ribcage at sternum by cutting away sides of ribcage, then cut vertically through the sternum to expose the trachea19. Cut away as much muscle and connective tissue as possible using fine scissors and #7 forceps without puncturing the trachea or lungs.
  5. Wrap the trachea in suture (size 2-0) as if to tie it off but without tightening. Nick trachea laterally and insert the catheter. Secure the suture tightly around the catheter by pulling the suture tight. Do not insert the catheter more than 1 cm into the lung.
  6. Inflate lungs with 1 mL of DPBS. Pull out the DPBS by slowly pulling back on the syringe. Re-inflate the lungs with the same DPBS and once again pull back on the syringe to harvest bronchoalveolar lavage fluid (BALF).
  7. Disconnect the syringe from the catheter, leaving the catheter inserted. Dispense BALF into a microcentrifuge tube.
  8. Fill the same 1 mL syringe with 1 mL of dispase and reattach to the catheter. Dispense syringe to inflate lungs with dispase. While removing the catheter, tighten the suture around the trachea to prevent leakage of dispase.
  9. Cut through the trachea laterally. Remove the lungs from the body cavity by cutting through the connective tissue along the back of the ribcage while using forceps to pull the lungs and trachea upwards.
  10. Remove the heart from the lungs. Place the lungs in 5 mL of DPBS on ice.
  11. At this step, take the separated BALF and spin down at 400 x g for 5 min at 4 °C. The supernatant may be aliquoted and stored as required. There should be a visible cell pellet that can be resuspended in 100 µL of RPMI.
    NOTE: One can wait up to 2 hr to proceed with digestion, which allows multiple mice to be harvested at a time.

3. Digesting the lungs

  1. Prepare the digest mix. Add 83 µg/mL liberase (50 µL stock solution), and 100 µg/mL DNAse (15 µL stock solution) in 3 mL of RPMI per lung.
  2. Dissect the five lobes of the lungs and discard any connective tissue19,20. Chop the lung with scissors for 1 min on a glass slide.
  3. Transfer the chopped lung into a 50 mL centrifuge tube using dissection scissors. Add cell pellet recovered from BALF and resuspended in RPMI into the centrifuge tube. Add 3 mL of digest mix to the tube containing the sample using a 5 mL serological pipette.
  4. Pipet lung digest mixture up and down 2-3 times. Place at 37 °C in an orbital shaker at 140 rpm with digestion tubes placed at a 45-degree angle for 40 min.

4. Preparing the single-cell suspension

  1. Remove the 50 mL centrifuge tubes from the orbital shaker and place them on ice. Pipette lung digest mixture up and down 5-6 times. Filter through a 70 μm cell strainer into a new 50 mL tube. Wash any remaining cells through the filter and neutralize enzymes with 10 mL 5% FBS in RPMI.
  2. Spin for 5 min 4 °C at 600 x g. Aspirate the supernatant using a vacuum aspirator or pipette. Resuspend in 1 mL of ACK lysis buffer and incubate for 3 min at room temperature to lyse red blood cells (RBCs). Add 9 mL of PBS and pipette up and down.
  3. Spin for 5 min at 4 °C at 600 x g. Aspirate supernatant using a vacuum aspirator or pipette. Resuspend in 1 mL of FACS buffer (1% FBS in PBS) and filter through 64 μm mesh into a microcentrifuge tube using a p1000 pipette.

5. Flow cytometry and downstream analyses

  1. If performing flow cytometry or fluorescence-activated cell sorting in a 96-well plate, stain approximately 1-2 million cells per well, or an 8% fraction of the lung suspension.
  2. Spin the cells down. All spins in a 96-well plate should be performed for 2.5 min (4 °C) at 600 x g. Flick off the supernatant and wash cells once by resuspending in 200 μL of DPBS. Spin down and flick.
  3. If cells are to be stained for flow cytometry analysis, proceed with the following staining procedure.
    1. Resuspend cells in live/dead Zombie stain (1:150) and Fc block (1:250) in 25 μL of DPBS for 10 min at room temperature in the dark.
    2. Prepare the antibody staining mix at a 2x concentration in the FACS buffer.
      NOTE: A staining mix should include all of the markers in the myeloid panel (Table 1) or epithelial panel (Table 2) at their indicated concentrations.
    3. Add 25 μL of staining mix to 25 μL of lung suspension in a plate and incubate on ice for 30 min in the dark. The total staining volume should now be 50 μL, and primary antibodies should be at their final 1x staining concentration.
    4. Add 150 µL of FACS buffer, spin down for 2.5 min at 4 °C at 600 x g, and flick off the supernatant. Wash twice in 200 μL of FACS buffer.
    5. If intracellular staining is required, fix the cells with an intracellular fixation kit. If intracellular staining is not required, cells may be fixed for 20 min in 4% PFA in DPBS.
    6. Wash off the fixative with 200 μL of FACS buffer three times. Samples may be stored resuspended in 200 μL of FACS buffer at 4 °C in the dark for 2-3 days. Before running samples, counting beads may be added to quantify cell numbers.
  4. If cells are to be sorted, proceed with the following staining procedure.
    1. Resuspend cells in 1x staining antibody mix with Fc block (1:250). Incubate for 30 min on ice in the dark.
    2. Add 150 μL of FACS buffer, spin down for 2.5 min at 4 °C at 600 x g, and flick off the supernatant. Wash three times with 200 μL of FACS buffer and resuspend in 200 μL of FACS buffer before sorting.
      NOTE: It is recommended to add a viability dye, such as DAPI, to cells before sorting.

Results

A successful digest will result in approximately 20-25 million cells with 90%-95% viability. If approximately 25,000 counting beads are added to an 8% fraction of the lung, beads should compromise 1%-3% of collected events. After gating on singlets, approximately 90%-95% of cells should be Zombie Aqua negative (indicating viability) (Figure 2A, Figure 3A).

Of CD45+ cells, CD64+F4/80+ cells are defined ...

Discussion

This protocol outlines a mouse lung digest that isolates approximately 20-25 million cells per mouse with 90%-95% viability. It additionally allows for the collection of BALF for further analysis. The resultant cell suspension is compatible with multiple laboratory techniques, including flow cytometry and fluorescence-activated cell sorting to isolate cells for sequencing or cell culture. Briefly, after perfusion, BALF is collected, and lungs are inflated with dispase. Lungs are then chopped and digested in a liberase/DN...

Disclosures

The authors have nothing to disclose.

Acknowledgements

This work was supported in part by grants from the National Institutes of Health (R35GM150816 and P30DK043351), Charles H. Hood Foundation, and Harvard Stem Cell Institute. We thank Alexander Mann and all other members of the Franklin laboratory for their help and advice in designing and refining the flow cytometry gating schemes and analyses. We also thank the Immunology Flow Cytometry Core at Harvard Medical School. Flow cytometry analysis was performed using FlowJo. Figure schematics were created using BioRender.

Materials

NameCompanyCatalog NumberComments
1 mL syringe with Slip TipVWRBD309659
1.7 mL microcentrifuge tubeDOT ScientificRN1700-GMT
10 mL pipettes (disposable)Fisher Scientific12-567-603
10 mL Syringe with BD Luer-Lok TipVWR75846-756
123 count eBeads Counting BeadsThermo Scientific01-1234-42
12-channel pipette (30-300ul)USA Scientific 7112-3300
16% paraformaldehydeVWR100503-917
23 G needle with regular bevelVWR305194
27 G needle with regular bevelVWRBD305109
5 mL pipettes (disposable)Thermo Fisher Scientific170373
50 mL centrifuge tubesOlympus 28-108
96-well round bottom plateCorning3797
ACK lysing bufferGibcoA100492-01
Alexa Fluor 488 anti-mouse CD11cBioLegend117311
Anti-F4/80 Rat Monoclonal Antibody (PE (Phycoerythrin)/Cy7)BioLegend123114
APC anti-mouse CD64 (FcγRI)BioLegend139306
APC/Cyanine7 anti-mouse CD45BioLegend103115
BD Insyte Autoguard Shielded IV CathetersVWR381423
Brilliant Violet 421 anti-mouse I-A/I-E (MHC-II)BioLegend107632
Brilliant Violet 421 anti-mouse/human CD11bBioLegend101235
Brilliant Violet 605 anti-mouse Ly-6CBioLegend128036
Brilliant Violet 711 anti-mouse CD45BioLegend103147
C57BL/6J mice Jackson Laboratories
Cd140a (PDGFRA) Monoclonal Antibody (APA5), PE-Cyanine7, eBioscienceLife Technologies25-1401-82
CD170 (Siglec F) Monoclonal Antibody (1RNM44N), PELife Technologies12170280
Cell strainersCorning352350
CentrifugeEppenodorfCentrifuge 5910R
Deoxyribonuclease I from bovine pancreas (DNase)Millipore SigmaDN25-100MGReconstituted at 20 mg/mL in DPBS as stock solution stored at -20 °C
DispaseVWR76176-668Thawed once and stored as 1mL aliquots at -20 °C
Dissection forceps (Dumont #7)Fine Science Tools11297-00
Dissection scissorsFine Science Tools14060-09
DPBSThermo Fisher Scientific14190250
eBioscience fixation kitLife Technologies00-5523-00
EDTALife TechnologiesAM9260G
EthanolVWRTX89125170HU
FBSGeminiBio100-106Thawed once and heat-inactivated before long-term storage as aliquots at -20 °C
FITC anti-mouse CD31 AntibodyBioLegend102406
Gibco RPMI 1640 MediumFisher Scientific11-875-093
Glass slidesFisher Scientific12-552-3
graduated reservoirUSA Scientific 1930-2235
Ice bucketCorning432128
Ketamine hydrocholoride injection (100 mg/mL)DechraKetamine and xyalazine euthanization mixture can be kept at 30 mg/mL ketamine hydrochloride and 4.5mg/mL xylazine in sterile DPBS for up to one month.
LiberaseMillipore Sigma5401119001Reconstituted at 5 mg/mL in DPBS as stock solution stored at -20 °C
Lids for 96-well platesFisher Scientific07-201-731
Orbital Incubator ShakerBarnstead Lab-LineSHKE4000
p1000 pipetteEppenodorf3123000063
p1000 tipsUSA Scientific 1122-1830
p200 pipetteEppenodorf3123000055
p200 tipsUSA Scientific 1110-1700
PE anti-mouse CD326 (Ep-CAM)BioLegend118206
PerCP/Cyanine5.5 anti-mouse CD104 AntibodyBioLegend123614
PerCP/Cyanine5.5 anti-mouse Ly-6GBioLegend127616
Pipet-Aid Drummond4-000-101
Purified anti-mouse CD16/32 BioLegend101302Referred to as "Fc block" in text
Spray bottleVWR23609-182
Suture (Size 2-0)VWR100190-026
UnderpadsVWR56617-014
Xysed (xylazine 100mg/mL)PivetalSee ketamine hydrocholoride notes above. 
Zombie Aqua Fixable Viability KitBioLegend423102

References

  1. Wanner, A., Salathé, M., O'Riordan, T. G. Mucociliary clearance in the airways. Am J Respir Crit Care Med. 154 (6), 1868-1902 (1996).
  2. Mason, R. J., Williams, M. C. Type II alveolar cell. Defender of the alveolus. Am Rev Respir Dis. 115 (1), 81-91 (1977).
  3. Fehrenbach, H. Alveolar epithelial type II cell: defender of the alveolus revisited. Respir Res. 2 (1), 33-46 (2001).
  4. Basil, M. C., Alysandratos, K. -. D., Kotton, D. N., Morrisey, E. E. Lung repair and regeneration: Advanced models and insights into human disease. Cell Stem Cell. 31 (4), 439-454 (2024).
  5. Hussell, T., Bell, T. J. Alveolar macrophages: plasticity in a tissue-specific context. Nat Rev Immunol. 14 (2), 81-93 (2014).
  6. Gschwend, J., et al. Alveolar macrophages rely on GM-CSF from alveolar epithelial type 2 cells before and after birth. J Exp Med. 218 (1), e20210745 (2021).
  7. Gillich, A., et al. Capillary cell-type specialization in the alveolus. Nature. 586 (7831), 785-789 (2020).
  8. Schyns, J., et al. Non-classical tissue monocytes and two functionally distinct populations of interstitial macrophages populate the mouse lung. Nat Commun. 10 (1), 3964 (2019).
  9. Chakarov, S., et al. Two distinct interstitial macrophage populations coexist across tissues in specific subtissular niches. Science. 363 (6432), eaat3773 (2019).
  10. Tsukui, T., et al. Collagen-producing lung cell atlas identifies multiple subsets with distinct localization and relevance to fibrosis. Nat Commun. 11 (1), 1920 (1920).
  11. Aegerter, H., et al. Influenza-induced monocyte-derived alveolar macrophages confer prolonged antibacterial protection. Nat Immunol. 21 (2), 145-157 (2020).
  12. Johansson, C., Kirsebom, F. C. M. Neutrophils in respiratory viral infections. Mucosal Immunol. 14 (4), 815-827 (2021).
  13. Li, F., et al. Monocyte-derived alveolar macrophages autonomously determine severe outcome of respiratory viral infection. Sci Immunol. 7 (71), eabj5761 (2022).
  14. Moll, H. P., et al. Orthotopic transplantation of syngeneic lung adenocarcinoma cells to study PD-L1 expression. J Vis Exp. (143), e58101 (2019).
  15. Warshamana, G. S., Corti, M., Brody, A. R. TNF-α, PDGF, TGF-β1 expression by primary mouse bronchiolar-alveolar epithelial and mesenchymal cells: TNF-α induces TGF-β1. Exp Mol Pathol. 71 (1), 13-33 (2001).
  16. Corti, M., Brody, A. R., Harrison, J. H. Isolation and primary culture of murine alveolar type II cells. Am J Respir Cell Mol Biol. 14 (3), 309-315 (1996).
  17. Quantius, J., et al. Influenza virus infects epithelial stem/progenitor cells of the distal lung: Impact on Fgfr2b-driven epithelial repair. PLoS Pathog. 12 (5), e1005544 (2016).
  18. Wu, J., et al. Transcardiac perfusion of the mouse for brain tissue dissection and fixation. BIO Protoc. 11 (8), e3988 (2021).
  19. Morton, J., Snider, T. A. Guidelines for collection and processing of lungs from aged mice for histological studies. Pathobiol Aging Age Relat Dis. 7 (1), 1313676 (2017).
  20. Bijgaart, R. J. E., van den Kong, N., Maynard, C., Plaks, V. Ex vivo live imaging of lung metastasis and their microenvironment. J Vis Exp. (108), e53741 (2016).
  21. Shi, W., et al. Isolation and purification of immune cells from the liver. Int Immunopharmacol. 85, 106632 (2020).
  22. Short, K. R., et al. Influenza virus damages the alveolar barrier by disrupting epithelial cell tight junctions. Eur Respir J. 47 (3), 954-966 (2016).
  23. Laidlaw, B. J., et al. CD4+ T cell help guides formation of CD103+ lung-resident memory CD8+ T cells during influenza viral infection. Immunity. 41 (4), 633-645 (2014).
  24. D'Agostino, M. R., et al. Protocol for isolation and characterization of lung tissue-resident memory T cells and airway-trained innate immunity after intranasal vaccination in mice. STAR Protoc. 3 (2), 101652 (2022).
  25. Waal, A. M., de Hiemstra, P. S., Ottenhoff, T. H., Joosten, S. A., vander Does, A. M. Lung epithelial cells interact with immune cells and bacteria to shape the microenvironment in tuberculosis. Thorax. 77 (4), 408-416 (2022).
  26. Bhattacharya, J., Westphalen, K. Macrophage-epithelial interactions in pulmonary alveoli. Semin Immunopathol. 38 (4), 461-469 (2016).

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Explore More Articles

Mouse LungImmune CellsEpithelial CellsSingle cell SuspensionFlow CytometryFluorescence activated Cell SortingBronchoalveolar LavageLiberase MixtureMyeloid Cell SubsetsIntercellular CrosstalkLung BiologyDisease ProgressionTherapeutic Targets

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved